Department of Quantitative Biomedicine, University of Zurich, 8057 Zurich, Switzerland.
Gene Lay Institute of Immunology and Inflammation, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Immunity. 2024 Feb 13;57(2):206-222. doi: 10.1016/j.immuni.2024.01.010.
LAG-3, TIM-3, and TIGIT comprise the next generation of immune checkpoint receptors being harnessed in the clinic. Although initially studied for their roles in restraining T cell responses, intense investigation over the last several years has started to pinpoint the unique functions of these molecules in other immune cell types. Understanding the distinct processes that these receptors regulate across immune cells and tissues will inform the clinical development and application of therapies that either antagonize or agonize these receptors, as well as the profile of potential tissue toxicity associated with their targeting. Here, we discuss the distinct functions of LAG-3, TIM-3, and TIGIT, including their contributions to the regulation of immune cells beyond T cells, their roles in disease, and the implications for their targeting in the clinic.
LAG-3、TIM-3 和 TIGIT 构成了新一代免疫检查点受体,正在临床中得到应用。尽管最初是研究它们在抑制 T 细胞反应方面的作用,但在过去几年中,大量研究开始确定这些分子在其他免疫细胞类型中的独特功能。了解这些受体在免疫细胞和组织中调节的不同过程,将为拮抗或激动这些受体的治疗方法的临床开发和应用提供信息,以及与它们的靶向相关的潜在组织毒性的特征。在这里,我们讨论了 LAG-3、TIM-3 和 TIGIT 的不同功能,包括它们对 T 细胞以外的免疫细胞的调节作用、它们在疾病中的作用,以及它们在临床中的靶向意义。